Literature DB >> 21240298

Light chain amyloidosis: a case presentation and review.

Gavin M Melmed1.   

Abstract

Entities:  

Year:  2009        PMID： 21240298      PMCID： PMC2709094          DOI： 10.1080/08998280.2009.11928533

Source DB:  PubMed          Journal:  Proc (Bayl Univ Med Cent)        ISSN： 0899-8280


× No keyword cloud information.
  20 in total

1.  "Primary" systemic amyloidosis and myeloma. Discussion of relationship and review of 81 cases.

Authors:  R A KYLE; E D BAYRD
Journal:  Arch Intern Med       Date:  1961-03

2.  Treatment with oral melphalan plus dexamethasone produces long-term remissions in AL amyloidosis.

Authors:  Giovanni Palladini; Paola Russo; Mario Nuvolone; Francesca Lavatelli; Vittorio Perfetti; Laura Obici; Giampaolo Merlini
Journal:  Blood       Date:  2007-07-15       Impact factor: 22.113

Review 3.  Amyloidosis: a final common pathway for protein deposition in tissues.

Authors:  M J Stone
Journal:  Blood       Date:  1990-02-01       Impact factor: 22.113

4.  A trial of three regimens for primary amyloidosis: colchicine alone, melphalan and prednisone, and melphalan, prednisone, and colchicine.

Authors:  R A Kyle; M A Gertz; P R Greipp; T E Witzig; J A Lust; M Q Lacy; T M Therneau
Journal:  N Engl J Med       Date:  1997-04-24       Impact factor: 91.245

Review 5.  Light chain deposition disease with renal involvement: clinical characteristics and prognostic factors.

Authors:  Claudio Pozzi; Marco D'Amico; Giovanni B Fogazzi; Simona Curioni; Franco Ferrario; Sonia Pasquali; Giacomo Quattrocchio; Cristiana Rollino; Siro Segagni; Francesco Locatelli
Journal:  Am J Kidney Dis       Date:  2003-12       Impact factor: 8.860

6.  Spectrum of glomerular and tubulointerstitial renal lesions associated with monotypical immunoglobulin light chain deposition.

Authors:  P W Sanders; G A Herrera; K A Kirk; C W Old; J H Galla
Journal:  Lab Invest       Date:  1991-04       Impact factor: 5.662

7.  High-dose melphalan versus melphalan plus dexamethasone for AL amyloidosis.

Authors:  Arnaud Jaccard; Philippe Moreau; Veronique Leblond; Xavier Leleu; Lotfi Benboubker; Olivier Hermine; Christian Recher; Bouchra Asli; Bruno Lioure; Bruno Royer; Fabrice Jardin; Frank Bridoux; Bernard Grosbois; Jérome Jaubert; Jean-Charles Piette; Pierre Ronco; Fabrice Quet; Michel Cogne; Jean-Paul Fermand
Journal:  N Engl J Med       Date:  2007-09-13       Impact factor: 91.245

8.  Circulating peripheral blood plasma cells as a prognostic indicator in patients with primary systemic amyloidosis.

Authors:  Animesh Pardanani; Thomas E Witzig; Georgene Schroeder; Edwin A McElroy; Rafael Fonseca; Angela Dispenzieri; Martha Q Lacy; John A Lust; Robert A Kyle; Philip R Greipp; Morie A Gertz; S Vincent Rajkumar
Journal:  Blood       Date:  2002-09-05       Impact factor: 22.113

Review 9.  Amyloidosis (AL). Clinical and laboratory features in 229 cases.

Authors:  R A Kyle; P R Greipp
Journal:  Mayo Clin Proc       Date:  1983-10       Impact factor: 7.616

10.  Urinary findings in renal light chain-derived amyloidosis and light chain deposition disease.

Authors:  Gavin M Melmed; Andrew Z Fenves; Marvin J Stone
Journal:  Clin Lymphoma Myeloma       Date:  2009-06
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.